Calcineurin activation is not necessary for doxorubicin-induced hypertrophy in H9c2 embryonic rat cardiac cells: Involvement of the phosphoinositide 3-kinase-akt pathway

Journal of Pharmacology and Experimental Therapeutics

Volumn 319, Issue 2, 2006, Pages 934-940

  Merten, Kevyn E ^a   Jiang, Youchun ^a   Feng, Wenke ^a   Kang, Y James ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; CALCINEURIN; CALCIUM; CYCLOSPORIN A; DOXORUBICIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN SERINE THREONINE KINASE; TRANSCRIPTION FACTOR NFAT; TSUKUBAENOLIDE;

ANIMAL CELL; ARTICLE; CALCIUM CELL LEVEL; CELL ACTIVATION; CELL VOLUME; CONTROLLED STUDY; HEART MUSCLE CELL; HEART VENTRICLE HYPERTROPHY; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CONTENT; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; CALCINEURIN; CARDIOMEGALY; CELL LINE; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; ENZYME ACTIVATION; MYOCYTES, CARDIAC; NFATC TRANSCRIPTION FACTORS; PROTO-ONCOGENE PROTEINS C-AKT; RATS; SIGNAL TRANSDUCTION; TACROLIMUS;

EID: 33751170254     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.106.108845     Document Type: Article

References (40)

1. Cantley LC (2002) The phosphoinositide 3-kinase pathway. Science (Wash DC) 296:1655-1657.
2. Chen QM, Tu VC, Purdon S, Wood J, and Dilley T (2001) Molecular mechanisms of cardiac hypertrophy induced by toxicants. Cardiovasc Toxicol 1:267-283.
3. Chen QM, Tu VC, Wu Y, and Bahl JJ (2000) Hydrogen peroxide dose dependent induction of cell death or hypertrophy in cardiomyocytes. Arch Biochem Biophys 373:242-248.
4. Crabtree GR and Olson EN (2002) NFAT signaling: choreographing the social lives of cells. Cell 109:S67-S79.
5. Davies KJ and Doroshow JH (1986) Redox cycling of anthracyclines by cardiac mitochondria: I. Anthracycline radical formation by NADH dehydrogenase. J Biol Chem 261:3060-3067.
6. Deres P, Halmosi R, Toth A, Kovacs K, Palfi A, Habon T, Czopf L, Kalai T, Hideg K, Sumegi B, et al. (2005) Prevention of doxorubicin-induced acute cardiotoxicity by an experimental antioxidant compound. J Cardiovasc Pharmacol 45:36-43.
7. Ding B, Price RL, Borg TK, Weinberg EO, Halloran PF, and Lorell BH (1999) Pressure overload induces severe hypertrophy in mice treated with cyclosporine, an inhibitor of calcineurin. Circ Res 84:729-734.
8. Doroshow JH and Davies KJ (1986) Redox cycling of anthracyclines by cardiac mitochondria. II. Formation of superoxide anion, hydrogen peroxide, and hydroxyl radical. J Biol Chem 261:3068-3074.
9. (2+) response in mutant sarcomere protein-mediated familial hypertrophic cardiomyopathy. J Clin Investig 106:1351-1359.
10. Ferrans VJ (1978) Overview of cardiac pathology in relation to anthracycline cardiotoxicity. Cancer Treat Rep 62:955-961.
11. Frey N and Olson EN (2003) Cardiac hypertrophy: the good, the bad, and the ugly. Annu Rev Physiol 65:45-79.
12. Fruman DA, Pai SY, Klee CB, Burakoff SJ, and Bierer BE (1996) Measurement of calcineurin phosphatase activity in cell extracts. Methods 9:146-154.
13. Ha T, Li Y, Gao X, McMullen JR, Shioi T, Izumo S, Kelley JL, Zhao A, Haddad GE, Williams DL, et al. (2005) Attenuation of cardiac hypertrophy by inhibiting both mTOR and NFkappaB activation in vivo. Free Radic Biol Med 39:1570-1580.
14. Hescheler J, Meyer R, Plant S, Krautwurst D, Rosenthal W, and Schultz G (1991) Morphological, biochemical, and electrophysiological characterization of a clonal cell (H9c2) line from rat heart. Circ Res 69:1476-1486.
15. Ho KK, Pinsky JL, Kannel WB, and Levy D (1993) The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol 22:6A-13A.
16. Jung K and Reszka R (2001) Mitochondria as subcellular targets for clinically useful anthracyclines. Adv Drug Deliv Rev 49:87-105.
17. Kalivendi SV, Konorev EA, Cunningham S, Vanamala SK, Kaji EH, Joseph J, and Kalyanaraman B (2005) Doxorubicin activates nuclear factor of activated T-lymphocytes and Fas ligand transcription: role of mitochondrial reactive oxygen species and calcium. Biochem J 389:527-539.
18. Kang YJ, Chen Y, and Epstein PN (1996) Suppression of doxorubicin cardiotoxicity by overexpression of catalase in the heart of transgenic mice. J Biol Chem 271:12610-12616.
19. Kang YJ, Chen Y, Yu A, Voss-McCowan M, and Epstein PN (1997) Overexpression of metallothionein in the heart of transgenic mice suppresses doxorubicin cardiotoxicity. J Clin Investig 100:1501-1506.
20. Kang YJ, Zhou ZX, Wang GW, Buridi A, and Klein JB (2000) Suppression by metallothionein of doxorubicin-induced cardiomyocyte apoptosis through inhibition of p38 mitogen-activated protein kinases. J Biol Chem 275:13690-13698.
21. Kenessey A and Ojamaa K (2006) Thyroid hormone stimulates protein synthesis in the cardiomyocyte by activating the Akt-mTOR and p70S6K pathways. J Biol Chem 281:20666-20672.
22. Li X, Lu Y, Liang K, Liu B, and Fan Z (2005) Differential responses to doxorubicin-induced phosphorylation and activation of Akt in human breast cancer cells. Breast Cancer Res 7:589-597.
23. Lloyd-Jones DM, Larson MG, Leip EP, Beiser A, D'Agostino RB, Kannel WB, Murabito JM, Vasan RS, Benjamin EJ, and Levy D (2002) Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation 106:3068-3072.
24. Luo Z, Shyu KG, Gualberto A, and Walsh K (1998) Calcineurin inhibitors and cardiac hypertrophy. Nat Med 4:1092-1093.
25. Matsui T, Li L, Wu JC, Cook SA, Nagoshi T, Picard MH, Liao R, and Rosenzweig A (2002) Phenotypic spectrum caused by transgenic overexpression of activated Akt in the heart. J Biol Chem 277:22896-22901.
26. Merten KE, Feng W, Zhang L, Pierce W, Cai J, Klein JB, and Kang YJ (2005) Modulation of cytochrome C oxidase-va is possibly involved in metallothionein protection from doxorubicin cardiotoxicity. J Pharmacol Exp Ther 315:1314-1319.
27. Molkentin JD, Lu JR, Antos CL, Markham B, Richardson J, Robbins J, Grant SR, and Olson EN (1998) A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 93:215-228.
28. Müller JG, Nemoto S, Laser M, Carabello BA, and Menick DR (1998) Calcineurin inhibition and cardiac hypertrophy. Science (Wash DC) 282:1007.
29. Myers CE, McGuire WP, Liss RH, Ifrim I, Grotzinger K, and Young RC (1977) Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response. Science (Wash DC) 197:165-167.
30. Naga Prasad SV, Esposito G, Mao L, Koch WJ, and Rockman HA (2000) Gβγ-dependent phosphoinositide 3-kinase activation in hearts with in vivo pressure overload hypertrophy. J Biol Chem 275:4693-4698.
31. Schmitt JP, Semsarian C, Arad M, Gannon J, Ahmad F, Duffy C, Lee RT, Seidman CE, and Seidman JG (2003) Consequences of pressure overload on sarcomere protein mutation-induced hypertrophic cardiomyopathy. Circulation 108:1133-1138.
32. Shioi T, Kang PM, Douglas PS, Hampe J, Yballe CM, Lawitts J, Cantley LC, and Izumo S (2000) The conserved phosphoinositide 3-kinase pathway determines heart size in mice. EMBO (Eur Mol Biol Organ) J 19:2537-2548.
33. Shioi T, McMullen JR, Kang PM, Douglas PS, Obata T, Franke TF, Cantley LC, and Izumo S (2002) Akt/protein kinase B promotes organ growth in transgenic mice. Mol Cell Biol 22:2799-2809.
34. Sun X, Zhou Z, and Kang YJ (2001) Attenuation of doxorubicin chronic toxicity in metallothionein-overexpressing transgenic mouse heart. Cancer Res 61:3382-3387.
35. Sussman MA, Lim HW, Gude N, Taigen T, Olson EN, Robbins J, Colbert MC, Gualberto A, Wieczorek DF, and Molkentin JD (1998) Prevention of cardiac hypertrophy in mice by calcineurin inhibition. Science (Wash DC) 281:1690-1693.
36. Tu VC, Bahl JJ, and Chen QM (2002) Signals of oxidant-induced cardiomyocyte hypertrophy: key activation of p70 S6 kinase-1 and phosphoinositide 3-kinase. J Pharmacol Exp Ther 300:1101-1110.
37. Wang Y, Huang S, Sah VP, Ross J Jr, Brown JH, Han J, and Chien KR (1998) Cardiac muscle cell hypertrophy and apoptosis induced by distinct members of the p38 mitogen-activated protein kinase family. J Biol Chem 273:2161-2168.
38. Wilkins BJ, Dai YS, Bueno OF, Parsons SA, Xu J, Plank DM, Jones F, Kimball TR, and Molkentin JD (2004) Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy. Circ Res 94:110-118.
39. Zechner D, Thuerauf DJ, Hanford DS, McDonough PM, and Glembotski CC (1997) A role for the p38 mitogen-activated protein kinase pathway in myocardial cell growth, sarcomeric organization, and cardiac-specific gene expression. J Cell Biol 139:115-127.
40. Zhang W, Kowal RC, Rusnak F, Sikkink RA, Olson EN, and Victor RG (1999) Failure of calcineurin inhibitors to prevent pressure-overload left ventricular hypertrophy in rats. Circ Res 84:722-728.